Dependence on Human Growth Hormone Products and Single-Supplier Risk
First written in FY2016. 7 of 12 entries say "Mitigated", first in FY2018. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026MitigatedAnnual report
「Human growth hormone products will account for 44.5% of total sales in the current consolidated fiscal year among the Group's products.」
Dependence on human growth hormone products declined from 54.7% in the previous fiscal year to 44.5%. The policy of reducing dependence by expanding products covered by J-Brain Cargo®, including Izcargo®, also continued. - 2026-05-13MitigatedRevision of earnings forecasts
「Human growth hormone product Growject® 18,098 17,933 △0.9 Mucopolysaccharidosis type II treatment Izcargo® intravenous infusion 5,718 6,766 18.3」
Sales of Growject® declined while Izcargo® sales increased, resulting in higher total sales. Based on the figures in the table, Growject®’s share of sales decreased from the previous fiscal year. - FY2025WorsenedAnnual report
「Human growth hormone products will account for 54.7% of total sales in the current consolidated fiscal year among the Group's products.」
Dependence on human growth hormone products increased from 41.8% in FY2024 to 54.7%. The policy of reducing dependence through products such as Izcargo® continued, but the proportion worsened in the current fiscal year. - FY2024WorsenedAnnual report
「Human growth hormone products will account for 41.8% of total sales in the current consolidated fiscal year among the Group's products.」
Dependence on human growth hormone products increased from 35.7% in FY2023 to 41.8%. The policy of reducing dependence through products such as Izcargo® continued, but the proportion worsened in the current fiscal year. - FY2023WorsenedAnnual report
「Human growth hormone products will account for 35.7% of total sales in the current consolidated fiscal year among the Group's products.」
Dependence on human growth hormone products increased from 25.3% in the previous fiscal year to 35.7%. The policy of reducing dependence over the medium to long term through growth in products such as Izcargo® continued, but the proportion increased in the current fiscal year. - FY2022MitigatedAnnual report
「Human growth hormone products will account for 25.3% of total sales in the current consolidated fiscal year among the Group's products.」
Dependence on human growth hormone products declined from 44.1% in the previous fiscal year to 25.3%. The disclosure describes the expansion of revenue sources, including Izcargo®, milestone revenue, and AZD1222 drug substance. - FY2021MitigatedAnnual report
「Human growth hormone products accounted for 44.1% of total sales in the current consolidated fiscal year among the Group's products.」
Dependence on human growth hormone products declined from 51.0% in the previous fiscal year to 44.1%. - FY2020MitigatedAnnual report
「Human growth hormone products will account for 51.0% of total sales in the current consolidated fiscal year among the Group's products.」
Dependence on human growth hormone products declined from 51.7% in the previous fiscal year to 51.0%. The risks of declining birth rates and future market contraction, dependence on Ferring for the active pharmaceutical ingredient, and supply risks for Growjector® L continued to be disclosed. - FY2019MitigatedAnnual report
「Human growth hormone products accounted for 55.8% of total sales in the previous consolidated fiscal year and 51.7% in the current consolidated fiscal year among the Group's products.」
Dependence on human growth hormone products declined from 55.8% to 51.7% of sales. The risk that Ferring is the sole supplier of the active pharmaceutical ingredient, and the response of securing inventory, continued to be disclosed. - FY2018MitigatedAnnual report
「Human growth hormone products accounted for 59.1% of total sales in the previous consolidated fiscal year and 55.8% in the current consolidated fiscal year among the Group's products.」
Dependence on human growth hormone products declined from 59.1% to 55.8% of sales. The risk that Ferring is the sole supplier of the active pharmaceutical ingredient, and the response of securing inventory sufficient for a specified period, continued to be disclosed. - FY2017WorsenedAnnual report
「Human growth hormone products accounted for 58.6% of total sales in the previous consolidated fiscal year and 59.1% in the current consolidated fiscal year among the Group's products.」
Dependence on human growth hormone products increased from 58.6% to 59.1% of sales. - FY2016First statedAnnual report
「Human growth hormone products accounted for 56.8% of total sales in the previous consolidated fiscal year and 58.6% in the current consolidated fiscal year among the Group's products. Accordingly, if grounds arise for revoking the marketing approval for these products, or if other circumstances cause sales to decline substantially, the Company's financial results may be affected.」
Disclosed that human growth hormone products accounted for 58.6% of sales. Also identified as a risk the fact that Ferring is the sole supplier of the active pharmaceutical ingredient.